VivoSeq
Other

Parapsoriasis

3

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Parapsoriasis is an early-stage landscape with 3 programs across 1 company. The most active players are UCB. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

100/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Bimekizumab

UCB

Phase 1
No programs
Phase 2
No programs
Phase 31

Infliximab

Organon and Co

Approved1

Bexarotene

Bausch Health Americas, Inc.

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Terminated1 · 100%

Clinical Trials

Trial Activity

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
Terminated·FFox Chase Cancer Center·Phase 2·NCT00322296·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)